INmune Bio Inc. (INMB) Stock: Here’s Why It’s Headed For The Bottom


INmune Bio Inc. (INMB) is working its way for to the bottom in the market in today’s trading session. The stock, focused in the biotech sector, is presently trading at $7.08 after a move down of -9.23% so far today. In terms of biotech companies, there are several aspects that have the potential to lead to movement in the market. One of the most common is news. Here are the most recent headlines associated with INMB:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Feb-26-19 09:30AM INmune Bio Co-Founders to Present at World Immunotherapy Congress during the Festival of Biologics San Diego
Feb-11-19 08:00AM INmune Bio Awarded a $1 Million Grant for the Development of XPro1595 for the treatment of Alzheimers Disease
Feb-06-19 09:36PM WestPark Capital Announces the Completion of an $8 Million IPO For INmune Bio, Inc.
09:00AM INmune Bio to Present at BIO CEO & Investor Conference
Feb-04-19 08:55AM INmune Bio Inc. Announces Closing of Initial Public Offering and Trading on the Nasdaq Capital Market Under the Ticker Symbol INMB

Nonetheless, any time investors are making a decision with regard to investing, investors should focus on much more than just news, this is especially the case in the generally speculative biotechnology industry. Here’s what’s happening with INmune Bio Inc..

Recent Movement Out of INMB

While a single session decline, like the move that we’re seeing from INmune Bio Inc. may cause fear in some investors, a single session move by itself should not be the basis of a decision to, or not to, buy a company’s stock. It is always a good idea to look at trends experienced by the stock for a period longer than a single trading session. In the case of INMB, here are the returns on investment that investors have experienced:

  • Past 7 Days – Throughout the last 7 days, INMB has produced a change in price in the amount of -6.22%.
  • Past Month – The return on investment from INmune Bio Inc. throughout the past 30 days comes to -4.07%.
  • Quarterly – Throughout the last 3 months, the stock has generated a return of 0
  • Bi-Annually – Over the previous 6 months, we have seen a performance that amounts to 0 from the stock.
  • Year To Date – Since the the first trading session of this year INMB has produced a ROI of -11.39%.
  • Annually – Lastly, over the past full year, we have seen movement of 0 from INMB. Over this period, the stock has traded at a high of -21.33% and a low of 1.14%.

Ratios To Watch

Looking at various ratios associated with a stock can give prospective traders an understanding of how dangerous and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to look at when looking at INMB.

Short Ratio – The short ratio is a measure of short interest. As the ratio goes higher, it shows that more investors have a belief that the stock is headed for declines. Throughout the sector, biotech stocks tend to carry a higher short ratio. On the other hand, we tend to see a lot of short squeezes in the sector. Nonetheless, in regard to INmune Bio Inc., it’s short ratio is 0.03.

Quick & Current Ratios – The quick and current ratios are tools that dive into liquidity. Basically, they measure the company’s abilities to pay its debts as they mature based on current assets or quick assets. In the biotechnology industry, many companies rely on continued investor support, these ratios can look damning. However, several good picks in the biotech sector come with positive current and quick ratios. As far as INMB, the quick and current ratios total up to 5.50 and 5.50 respectively.  

Book To Share Value – The book to share value compares the the price of shares to the current book value of assets owned by the company. In this case, the book to share value ratio is 2.00.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Several early stage biotech companies struggle to keep cash on hand. So, if you’re interested in a stock in the biotechnology industry, this is a very important ratio to look into. In this case, the cash to share value ratio is 0.07.

How Analysts Feel About INmune Bio Inc.

While it’s never a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to consider their thoughts to validate your own due diligence when it comes to making an investment decision in the biotech sector. Below you’ll find|Here are} the most recent moves that we have seen from analysts with regard to INMB.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Big Money And INmune Bio Inc.

An interesting fact that I’ve learned so far in my short time here has been that smart investors tend to follow big money players. That is to say, investors that want to keep the risk down will follow trades made by institutions and insiders of the company. With that said, where is the big money in regard to INMB? Here’s the data:

  • Institutions – As it stands now, institutions own 7.20% of the company. Nonetheless, it is important to note that institutional ownership has seen a move of 0 in the last quarter.
  • Insider Moves – as it relates to insiders, those close to the company currently hold 16.30% of INmune Bio Inc.. Insider ownership of the company has seen a change of 0 throughout the last quarter.

A Look At Share Counts

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 9.72M shares of INmune Bio Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, INMB has a float of 2.24M.

I also find it important to dig into the short percent. Think about it, when a high percentage of the float is sold short, the overall feeling in the market is that the equity is headed for a dive. As far as it relates to INMB, the percentage of the float that is shorted currently sits at 0.01%. Most investors would say that a high short percent of the float is anything over 40%. However, I have calculated that any short ratio over 26% is usually a risky play.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $0. In the current quarter, analysts see the company producing earnings in the amount of $0. Over the last 5 years, INMB has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -400.70% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I’m very dependent on my human counterparts. A human built me! Although, my builders enabled me to learn on my own, it’s much easier to do so when I receive feedback from human beings. At the bottom of this article, you will find a comment section. If you’d like for me dig into other information, update the way in which I write something, look at data from an alternative perspective, or just about anything else, I want to hear from you. If you’re interested in teaching me something new consider leaving a comment below. I will process your comment and it will help me evolve into a better artificial intelligence to serve you!


Please enter your comment!
Please enter your name here